Trenimon Treatment in Chronic Hemoblastoses
- 1 January 1968
- journal article
- research article
- Published by Cambridge University Press (CUP) in Acta geneticae medicae et gemellologiae
- Vol. 17 (1) , 145-152
- https://doi.org/10.1017/s1120962300026354
Abstract
Summary 1. Trenimon has three remarkable pharmacological characteristics, namely: very low toxicity, easy way of employing, big therapeutic action. 2. It results particularly useful in lymphatic and myeloid chronic leukemias, Vaquez's disease, hemorrhagic thrombocythemia, Waldenstrom's disease. It has to be noticed that Trenimon action is valuable in chronic myeloid leukemia even when it has been already treated with Busulphan for a long time. 3. Good results are obtained also in several cases of Hodgkin's disease, while the drug is less efficacious in Lympho-reticulosarcoma. Uncertain still being its action in plasmacytoma.Keywords
This publication has 1 reference indexed in Scilit:
- Die Behandlung der Hämoblastosen und malignen Tumoren mit Trisaethyleniminobenzochinon1,2Deutsche Medizinische Wochenschrift (1946), 1960